Objectives: Although metabolic syndrome is associated with increased sympathetic activity that chronically stimulates β-adrenoceptors, the β-adrenoceptor signaling pathway has been poorly studied in this situation. We studied the β-adrenoceptor signaling pathway in Zucker lean, obese, and obese diabetic rats.
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For information regarding this article, E-mail: bruno.riou@psl.aphp.fr Modification of the β-Adrenoceptor Stimulation Pathway in Zucker Obese and Obese Diabetic Rat Myocardium* higher morbidity and mortality. The key elements of metabolic syndrome are obesity, impaired glucose tolerance, insulin resistance, dyslipidemia, hypertension, and increased sympathetic activity, all factors that may lead to cardiac dysfunction and ultimately congestive heart failure (1) . Although obesity is associated with lower perioperative mortality (known as "obesity paradox"), patients with the metabolic syndrome are exposed to a higher mortality risk during the perioperative period (2) . Such obesity paradox has also been reported in critically ill patients (3) , including those with severe sepsis (4) . However, several large clinical studies challenge the validity of the obesity paradox (5) , and obese trauma patients are at risk of higher mortality from persistent hemorrhage (6) .
In diabetic patients, diastolic dysfunction and a reduced response to β-adrenoceptor stimulation are observed, which may contribute to hemodynamic instability during critical care and the perioperative period (7) . Although metabolic syndrome is associated with increased catecholamine levels and increased sympathetic activity that chronically stimulates β-adrenoceptors (8) , the β-adrenoceptor signaling pathway has been poorly studied in this situation. Conflicting results have been obtained in obese swine and rabbit concerning cardiac β-adrenoceptor expression (9) (10) (11) . The Zucker obese rat is considered as a reliable model of metabolic syndrome (12, 13) . Furthermore, this model enables the separate study of obesity and obesity associated with type 2 diabetic status (14) . We have previously observed alterations in β-adrenoceptor signaling pathway in type 1 diabetic (15) and senescent rats (16) . Although an increase in sympathetic nervous system activation is an important mechanism for maintaining cardiac output, the positive inotropic response to β-adrenoceptor stimulation is altered in type 1 diabetic rats, in part, owing to the down-regulation of β 1 -adrenoceptor and the up-regulation of β 3 -adrenoceptor, which is the source of a negative inotropic effect. Active efflux transporters, namely the multidrug resistance-associated protein 4 (MRP4), also act as an independent endogenous regulator of intracellular cyclic nucleotide levels (3′,5′-cyclic adenosine monophosphate, cAMP) (17) and has been recently shown to participate in β-adrenoceptor dysfunction during aging (18) .
The aim of this study was to compare the effects of β-adrenoceptor stimulation in Zucker lean (as the control group), Zucker obese (also known as "Zucker fatty rats"), and Zucker obese diabetic (also known as "Zucker diabetic fatty rats") rats in vitro using isolated left ventricular papillary muscle. Our hypothesis was that metabolic syndrome is associated with some degree of β-adrenergic dysfunction, which is aggravated when associated with diabetes. We precisely assessed the effects of β-adrenergic stimulation on both contraction and relaxation and particularly focused on the following possible mechanisms involved, that is, down-regulation of β 1 and up-regulation of β 3 -adrenoceptors (15, 16) and up-regulation of MRP4 (17, 18) .
MATERIALS AND METHODS
Experiments were conducted in accordance with the Principles of Laboratory Animal Care (NIH publication No. 86-23, revised 1985) in an authorized laboratory under supervision of an authorized researcher (J.A.; A-75-20-81). The project had been approved by the relevant Animal Care Committee through the French Ministry of Higher Education and Research (Comité Régional d'Ethique en Expérimentation Animale Paris-Comité 3, Paris, France). Animals were purchased from Charles River (Saint Germain sur l'Arbresle, France) and cared in a labeled housing place (agreement number B-75-13-08) with food and water ad libitum. Animals were fed with normal rat chow containing 10% of calories from fat, 67% from carbohydrates, and 23% from proteins, 2.791 kcal/g (A04-10, SAFE, Augy, France). Three groups of 15-week-old male rats were studied: 1) Zucker lean (fa/-) rats; 2) Zucker obese (fa/fa) rats; and 3) Zucker obese (fa/fa) diabetic rats (12, 14) . Because of the obvious morphological differences between groups, blinding was not possible.
Biological Measurements
Total cholesterol and triglyceride concentrations were determined by automated enzymatic methods (19, 20) , and glucose concentration was assayed by hexokinase-mediated reaction (21) on a Modular P chemistry analyzer (Roche Diagnostics, Meylan, France). C-peptide was measured by quantitative enzyme-linked immunosorbent assay (ELISA) kit provided by Mercodia France (Paris, France). Rat leptin and rat total adiponectin levels were quantified using ELISA kits provided by Bio-Vendor (Eurobio, Courtabeuf, France) and Alpco (Eurobio), respectively, and measurements were performed according to the manufacturer's instructions.
Isolated Left Ventricle Papillary Muscle
Shortly after induction of general anesthesia with pentobarbital, the heart was removed in bloc, dissected, and weighed. The left ventricular papillary muscles were carefully excised and suspended vertically in a Krebs-Henseleit bicarbonate buffer solution (118 mM NaCl, 4.7 mM KCl, 1.2 mM MgSO 4 , 1.1 mM KH 2 PO 4 , 25 mM NaHCO 3 , 2.5 mM CaCl 2 , and 4.5 mM glucose) maintained at 29°C with a thermostatic water circulator and bubbled with 95% oxygen and 5% CO 2 as previously described (22) . The papillary muscles were stimulated at 12 pulses/min for 60-minute stabilization period at the initial muscle length (L max ) at the apex of length-active isometric tension curve. The electromagnetic lever system has been described previously (22) . All analyses were made from digital records of force and length obtained with a computer. Conventional mechanical variables at L max were calculated from three twitches. The first twitch was isotonic and loaded with the preload corresponding to L max . The second twitch was rapidly clamped to zero load just after the electrical stimulus with a critical damping. The third twitch was fully isometric at L max . We determined the maximum unloaded shortening velocity (V max ) using the zero-load technique, and we determined maximum shortening ( max Vc) and lengthening ( max Vr) velocities and time to peak shortening (TPS) of the twitch with preload only. In addition, the maximum isometric active force normalized for cross-sectional area (AF), the peaks of the positive (+dF/dt) and the negative (-dF/ dt) force derivatives at L max normalized for cross-sectional area, www.ccmjournal.org e243 and the time to peak force (TPF) from the isometric twitch were recorded. Because changes in the contraction phase induce coordinated changes in the relaxation phase, indices of contraction-relaxation coupling have been developed to study lusitropy (23) . The R1 coefficient (R1 = max Vc/ max Vr) studies the coupling between contraction and relaxation under low load and thus lusitropy, in a manner that is independent of inotropic changes. R1 tests sarcoplasmic reticulum (SR) calcium uptake function (23) . The R2 coefficient (+dF/dt/-dF/dt) studies the coupling between contraction and relaxation under high load and thus lusitropy, in a manner that is less dependent on inotropic changes, and reflects the myofilament calcium sensitivity (23) . The cross-sectional area was calculated from the length and weight of papillary muscle, assuming a density of 1.
Since the contractility is nearly maximum at a calcium concentration of 2.5 mM in the rat myocardium, the extracellular calcium concentration was decreased from 2.5 to 0.5 mM to assess the inotropic response to β-adrenoceptor stimulations, as previously described (23) . A decrease in AF between 45% and 65% of baseline was required when calcium concentration was decreased. β-adrenoceptor stimulation was induced with increasing concentrations of isoproterenol (10 -8 to 10 -4 M), a nonselective β-adrenoceptor agonist, in the presence of phentolamine (10 -6 M) to block α-adrenoceptors (13) . The effect of isoproterenol was expressed by the percentage of baseline value of the maximal effect of isoproterenol on AF and V max (Eff max ) and the concentration of isoproterenol producing 50% of the maximal effect (C 50 ) (23) .
We also studied the effects of stimulation of adenylate cyclase using forskolin (5 × 10 -5 M) and the direct effect of dibutyryl cAMP (5 × 10 -4 M) as previously described (24) . All drugs were purchased from Sigma-Aldrich Chimie (l'Isle d'Abeau-Chesnes, France) and added volumes never exceed 2% of the total.
Immunoblotting
The left ventricles were removed from anesthetized rats and frozen in liquid nitrogen. Total proteins were extracted in a Triton 1% buffer with anti-phosphatase/protease inhibitor (Sigma-Aldrich). All protein concentrations were determined using Bradford reagent (BioRad, Marne-La-Coquette, France). After denaturation in Laemmli buffer, a fixed amount of mixed proteins was loaded in each lane of a sodium dodecyl sulfate polyacrylaminde gel electrophoresis (9-15%). Proteins are separated by electrophoresis in a migration buffer and then transferred to a nitrocellulose membrane (Hybond, GE Healthcare, Vélizy, France). After saturation in milk or bovine serum albumin, each membrane was incubated overnight at 4°C with primary antibodies: anti-sarcoplasmic reticulum Calcium ATPase (SERCA-2a) (1:2,500, Abcam, Paris, France), antiphospholamban (1:1,000, Thermo Fisher Scientific, Rockford, IL), anti-β 1adrenoceptor (1:1,000, Santa Cruz Biotechnology, Le Perray en Yvelines, France), anti-β 3 -adrenoceptor (1:1,000, Santa Cruz Biotechnology), anti-β 2 -adrenoceptor (1:1,000, Santa Cruz Biotechnology), and anti-MRP4 (multidrug-resistance protein 4) (1:200, Abcam), respectively. The following day, membranes were washed with Tris-buffered saline Tween and incubated with appropriate secondary antibody. Relative quantification of targeted protein was achieved by fluorescence recording on EthanDIGE reader with an ECL detection system (GE Healthcare, Vélizy, France). The SERCA 2a protein was detected at 110 kDa, phospholamban at 25 kDa, β 1 -adrenoceptor at 65 kDa, β 2 -adrenoceptor at 56-85 kDa, β 3 -adrenoceptor at 44 kDa, and MRP4 at 150 kDa. All Western blot experiments were quantified using Image J software (NIH, Bethesda, MD) and normalized versus glyceraldehyde 3-phosphate dehydrogenase (37 kDa), ensuring no variation in protein gel loading.
Statistical Analysis
Data are expressed as mean ± sd. Comparison of means was performed using the repeated-measures analysis of variance and Newman-Keuls test. All p values were two-tailed, and a p value of less than 0.05 was considered significant. Statistical analysis was performed using NCSS 2007 software (Statistical Solutions, Cork, Ireland). Concentration response curves were determined by fitting the data to the Hill sigmoid pharmacological model according to the following equation: Eff o = Eff max (1 + (C 50 C -1 ) n ) -1 in which Eff o is the observed effect, Eff max is the maximum effect, C 50 is the concentration that results in 50% of Eff max , C is the studied concentration, and n is the Hill coefficient. Iterative nonlinear regression curve fitting was used to obtain the best fit (Matlab 1.2c software; The MathWorks, South Natick, MA). The main endpoint of our study was the Eff max of the concentration-response curve of AF with isoproterenol. Assuming a value of Eff max of 179% ± 15% in the control group (15) , an α risk of 0.05, and a β risk of 0.20, we determined that a sample size of at least n = 7 papillary muscle per group would enable us to detect a 15% change in Eff max (PASS 11 software, Statistical Solutions).
RESULTS

Characterization of the Experimental Models
Obese rats had significantly higher body weight and heart weight than control rats, whereas obese diabetic rats did not significantly differ from control rats. The heart weight to body weight ratio was significantly decreased in obese rats mainly due to the greater increase in body weight than in heart weight ( Table 1 ). Blood glucose levels were elevated (four times) only in obese diabetic rats. The C-peptide level, which reflects the insulin secretion, was markedly increased in obese rats while it was moderately increased in obese diabetic rats despite high blood glucose levels, suggesting β-cell dysfunction. Total cholesterol and triglycerides levels in both obese and obese diabetic rats were significantly higher than control rats. The leptin levels were significantly increased in both obese and obese diabetic rats. Adiponectin levels were not significantly modified in both obese and obese diabetic rats when compared with control rats (Table 1) .
We measured the baseline characteristics of left ventricular papillary muscles in the different group of rats (Table 1) . Although V max was not significantly modified, a significant increase in AF was observed in obese and obese diabetic rats. Prolongation of the duration of contraction was observed in obese and obese diabetic rats as shown by the prolongation of TPS and TPF. No significant difference was observed in contraction-relaxation coupling under low load (R1, Table 1 ). By contrast, contraction-relaxation coupling under high load (R2) was significantly increased in obese diabetic rats (Table 1) .
β-Adrenergic
Stimulation β-adrenoceptor stimulation induced a marked positive inotropic effect in control rats ( Fig. 1 and Table 2) . A slight decrease in this inotropic response was observed in obese rats and a marked decrease was observed in obese diabetic rats in low (V max ) and high (AF) loading conditions ( Fig. 1 and Table 2 ).
In control rats, β-adrenoceptor stimulation induced a positive lusitropic effect under low load (R1) but not under high load (R2) ( Table 2) . Comparable effects were observed in control, obese, and obese diabetic rats, and there was no significant difference between strains ( Table 2 ). Figure 2 shows the comparison of the stimulation of β-adrenoceptors by isoproterenol, the stimulation of adenylate cyclase by forskolin, or direct stimulation by dibutyryl cAMP. The results obtained with forskolin were consistent with those obtained with isoproterenol, indicating a moderate impairment in the positive inotropic response in obese rats and a marked impairment in obese diabetic rats. By contrast, using dibutyryl cAMP, the degree of impairment in the positive inotropic response did not significantly differ between obese and obese diabetic rats (Fig. 2) .
Immunoblotting
In agreement with the functional changes observed in the papillary muscle experiments, we found that the abundance of proteins for β 1 -adrenoceptor were significantly reduced by 40% (p = 0.02) in obese rats and 54% (p = 0.003) in obese diabetic rats compared with levels measured in control rats Ratio of maximum shortening to maximum shortening velocity to maximum lengthening velocity (i.e., contraction relaxation coupling under low load) 0.55 ± 0.10 0.57 ± 0.16 0.60 ± 0.11
Ratio of the peak of positive force derivative to the peak negative force derivative (i.e., contraction relaxation coupling under low load)
1.71 ± 0.23 1.87 ± 0.28 2.08 ± 0.40 a L max = initial muscle length. a p < 0.05 versus control group. b p < 0.05 between obese and obese diabetic rats. Data are mean ± sd.
www.ccmjournal.org e245 (Fig. 3A) . A similar decrease was observed in β 2 -adrenoceptor protein (Fig. 3B) . By contrast, β 3 -adrenoceptors were not significantly modified in obese and obese diabetic rats (p = 0.97) ( Fig. 3C) . Consequently, the β 1/ β 3 and β 2/ β 3 ratios were significantly decreased in obese rats (2.4 ± 1.3, p = 0.01 and 1.8 ± 1.3, p = 0.03, respectively) and in obese diabetic rats (2.0 ± 1.0, p = 0.003 and 1.3 ± 0.8, p = 0.02, respectively) when compared with control rats (4.2 ± 1.3 and 4.8 ± 4.0, respectively). No significant changes were noted for phospholamban (p = 0.71) ( Fig. 3D) and MRP4 (p = 0.64) (Fig. 3F) . The abundance of SERCA 2a protein was significantly reduced by 40% (p = 0.03) in obese rats but not significantly modified in obese diabetic rats (p = 0.67) ( Fig.  3E) . But the SERCA 2a/phospholamban ratio was not significantly decreased (p = 0.61) in obese rat (3.5 ± 1.8) and obese diabetic rats (3.5 ± 1.8) when compared with control rats (3.9 ± 2.5).
DISCUSSION
In the present study, we observed a slight decrease in the positive inotropic effect of β-adrenoceptor stimulation in obese rats. In obese diabetic rats, the decrease was more pronounced but not as severe as that previously observed in type 1 diabetic Table 2 . AF = isometric active force normalized by cross-sectional area, V max = maximum shortening velocity. rats (11) (Fig. 4) . The main mechanism involved is probably the down-regulation of β 1 -and β 2 -adrenoceptors, which occurred without up-regulation of β 3 -adrenoceptor and without modification in MRP4. In Zucker obese rats, a single mutation A to C at nucleotide 880 (called "fa") in the leptin receptor gene on chromosome 5 causes a Gln to Pro substitution at residue 269 of the leptin receptor, leading to nonfunctional receptor. Zucker obese diabetic strain is a substrain selectively inbred for hyperglycemia, which carries an autosomal recessive defect in pancreatic β-cell transcription that is inherited independently of the fa mutation (25) . The gene involved in this diabetic profile has not been yet identified but requires the fa mutation to induce diabetes. The Zucker obese rat model is associated with moderate hypertension without significant cardiac dysfunction, whereas the Zucker obese diabetic model is associated with no hypertension but mild diastolic cardiac dysfunction. We observed important metabolic changes with a different profile in obese and obese diabetic rats. These two strains are known to be associated with hyperlipidemia due to high low-density lipoprotein and high-density lipoprotein cholesterol, increased lipoprotein lipase activity, hyperinsulinemia, and insulin resistance, whereas hyperglycemia is observed only in the obese diabetic strain (male only) (25) .
We did not observe noticeable myocardium dysfunction in obese and obese diabetic rats. AF was significantly increased in both obese and obese diabetic rats and associated with a prolongation of the contraction phase (increase in TPS and TPF). This prolongation of contraction has been previously reported in type I diabetic rats (15) and has been related to a slower cross-bridge cycling rate, a slower Ca 2+ release from the SR, and an alteration of I to potassium current.
A slight decrease in the positive inotropic response of β-adrenergic stimulation was observed in obese rats and a marked decrease in obese diabetic rats ( Fig. 1 and Table 2 ).
Conflicting results have been obtained in obese swine and obese rabbit (high-fat diet model) concerning cardiac β-adrenoceptor signaling pathway (9) (10) (11) . Lima-Leopoldo et al (26) concluded that no change occurs in cardiac function after β-adrenoceptor stimulation in obese rats, but a significant decrease was observed only at the highest concentration of isoproterenol, and the magnitude of the effect was comparable to our results. Our results suggest that the impairment in β-adrenergic signaling pathway is less severe in obese than in obese diabetic rats and less severe in obese diabetic than that previously observed in type 1 diabetic rats (15) .
The observed decreases in the responses to β-adrenoceptor stimulation in both obese and obese diabetic Zucker rats are consistently explained by the down-regulation of β 1 -and β 2 -adrenoceptors (Fig. 3A) . In Zucker obese rats, two earlier studies reported a decrease in β-adrenoceptor density but without separating β-adrenoceptor subtypes (27, 28) . Our results markedly differ from those previously observed in type 1 diabetic rats (streptozotocin-induced diabetes) in which β 1 -adrenoceptor down-regulation is associated with β 3 -adrenoceptor up-regulation (15) . This important difference may explain why the decrease in β-adrenoceptor stimulation was moderate in obese and obese diabetic Zucker rats in comparison to type 1 diabetic rats (15) . It is well established now that the stimulation of β 3 -adrenoceptors results in nitric oxide synthase-derived nitric oxide which is at the beginning of cyclic guanosine monophosphate production. Thereafter, cyclic guanosine monophosphate activates inhibitory G proteins and phosphodiesterases that increase the catabolism of the cAMP produced by the β 1 -and β 2 -adrenoceptors stimulation (29) and thus results in a negative inotropic effect (15, 30) . The down-regulation of β 1 -and β 2 -adrenoceptors in the heart of obese rats is consistent with the chronic sympathetic activation associated with the metabolic syndrome (31) and the catecholamine resistance of adipose tissue (32) . In contrast with type 1 diabetes (15), the lack of β 3 -adrenoceptor overexpression observed in obese and obese diabetic rats did not impact the inotropic effect induced by β 1 -and β 2 -adrenoceptors stimulation. In this way, we still observed a decreased response with dibutyryl cAMP administration in both obese and obese diabetic rats.
However, down-regulation of β 1 -and β 2 -adrenoceptors is probably not the sole mechanism involved in the decreased response to β-adrenoceptor stimulation. When the papillary muscles were directly stimulated by dibutyryl cAMP, we still observed a decreased response in both obese and obese diabetic rats, which were not significantly different between these two strains (Fig. 2 ). This suggests that some abnormality occurs downstream the adenylate cyclase level. Further studies are required to elucidate that mechanism, although our study clearly eliminates the role of MRP4 (Fig. 3E) , which has been recently demonstrated to be overexpressed during aging and to contribute to the decrease in β-adrenoceptor stimulation observed in old rats (19) . In the present study, the lack in overexpression of MRP4 and the modest decrease in cardiac contractile responsiveness observed in obese rats (Fig. 1) suggest www.ccmjournal.org e247 that this mechanism is of limited importance. To support this conclusion, when the production of cAMP by adenylate cyclase was directly stimulated using forskolin (Fig. 2) , we still observed a decreased response in both obese and obese diabetic rats, which was more pronounced in obese diabetic rats. These results contrast with those obtained in isolated membrane of heart cells in Zucker obese rats (25) . This discrepancy may be explained by the use of isolated membrane preparation and not intact papillary muscle. Thus, it is likely that several other mechanisms participate in the impairment in the β-adrenergic signaling pathway, one situated at the level of adenylate cyclase and the other downstream, beside the down-regulation of β 1 -and β 2 -adrenoceptors.
Lusitropy plays an important role in the maintenance of cardiac output. The lusitropic effect of β-adrenoceptor stimulation was not modified in either obese or obese diabetic rats. The decrease in SERCA 2a, which occurred without significant changes in the SERCA 2a/phospholamban ratio, did not impact the positive lusitropic effect of β-adrenergic stimulation. These results are consistent with those reported in type 1 diabetic rats in which the lusitropic effects of β-adrenoceptor stimulation were preserved, despite diabetic cardiomyopathy (33) . Such discrepancies between inotropic and lusitropic effects have been reported in other situations (24) and are probably related to the fact that smaller concentrations of cAMP are required to induce a maximal lusitropic effect (34) .
Catecholamines are widely used in critically ill patients but considerable intra-and interindividual variability exists in the response. Most previous studies have tried to elucidate pharmacokinetic and pharmacodynamic differences in catecholamine response (35, 36) , but very few have considered differences which may be linked to the baseline characteristics of the patient. Recently, Bauman et al (37) demonstrated that ethnic differences may be associated with significant difference in vasopressor requirements in patients with septic shock, but these authors did not look at genetic or phenotypic characteristics that might explain these differences. This study reported that the required doses of vasopressors were higher in Afro-American patients compared with white patients. However, the proportion of diabetic patients was also markedly different (68% vs 32%), and it is likely that the proportion of obese patients may also have been different, although this was not stated in the article. Future clinical research on the catecholamine requirements in the ICU should focus not only on genetic and phenotypic profile and catecholamine pharmacokinetics (35, 36) but also on the pathophysiologic conditions that may modify adrenoceptor signaling pathway.
The following limitations should be considered when assessing the clinical relevance of our results. First, this study was performed in rat myocardium, which differs from human myocardium. Second, no animal model of obesity and diabetes completely mimicks diseases observed in humans, and thus, it is important to acknowledge the limitations of the leptin/leptin receptor-based rodent model. For example, Zucker obese rats have only moderate hypertension, do not develop premature atherosclerosis, and their endothelium-dependent relaxation is not impaired, and Zucker obese diabetic rats do not develop sympathetic neuroaxonal dystrophy (25) . Thus, further studies in humans are required to validate our results. Third, we did not study changes observed after treatment of diabetes or food restriction in obesity. For example, it has been shown that food restriction may improve β-adrenergic stimulation in obese rats (28) .
In conclusion, we observed a slight decrease in the positive inotropic effect of β-adrenoceptor stimulation in Zucker obese rats, which was more pronounced in Zucker obese diabetic rats and mainly related to the down-regulation of β 1 -and β 2 -adrenoceptors. Figure 4 . Comparison of the β-adrenergic stimulation (isoproterenol) response in Zucker obese, Zucker obese diabetic (type 2), and Wistar diabetic (type 1) rats. The ratio is the ratio of Eff max in the disease strain to E max in their respective control strain. Eff max is the maximum effect on active isometric force of the concentration-effect curve of left ventricular papillary muscles exposed to increasing concentrations of isoproterenol. Data from type 1 diabetic rats (streptozotocin-induced diabetes) were obtained from Amour et al (15) . Data are mean ± sd. *p < 0.05 versus Zucker obese; †p < 0.05 versus Zucker obese diabetic rats.
